Kestra Medical Technologies Reports Strong Q1 2027 Earnings and Raises Guidance
Kestra Medical Technologies (NASDAQ: KMTS) reported a 60% year-over-year revenue growth in the first quarter of fiscal 2027, driven by market expansion, competitive share gains, and an increased mix of in-network patients. Management attributed this performance to its integrated care model and strategic territory management initiatives that are deepening account penetration. The company also noted favorable payer dynamics, including expanded coverage for non-ischemic patients from a major national insurer. Kestra raised its 2027 revenue guidance to $141 million from the previous estimate of $137 million and increased its long-term gross margin target to mid-70s. The company is leveraging AI tools to improve sales rep productivity, automate administrative tasks, and reduce operating expenses in pursuit of future profitability. A new $200 million term loan facility was secured for fleet expansion and commercial strategies. The VA represents a significant growth opportunity following Kestra's inclusion on the federal supply schedule six months ago.
Topics: gross margin expansion market penetration medical technology revenue growth